Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs for Ocular Corneal Burn
NCT03237442Phase 2Unknown
- Sponsor
- Guangzhou Saliai Stem Cell Science and Technology Co., Ltd.
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Corneal burn comparing UC-MSCs with Placebo (2 arms). Primary endpoint: the percent of cornea perforation at 3 months. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
Corneal burn
Beyond the preview
Go deeper on NCT03237442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237442.